Interventional technology firm Medtronic has finalized patient enrollment in its stent safety study known as PROTECT (Patient Related OuTcomes with Endeavor versus Cypher stenting Trial).
The Minneapolis-based firm has enrolled 8,800 patients at more than 200 medical centers worldwide in the study, which will compare the company's Endeavor drug-eluting stent to Johnson & Johnson's Cypher drug-eluting stent. The study's primary end point is overall stent thrombosis at three years, with secondary end points including death and nonfatal myocardial infarction, target lesion revascularization, and target vessel revascularization, Medtronic said.
The company expects that three-year data will be available in 2012.
Related Reading
Boston Scientific, Medtronic bury the hatchet, January 28, 2009
Medtronic installs MRI system in Canada, January 13, 2009
Medtronic debuts abdominal stent graft, November 19, 2008
Medtronic gets CE Mark for MRI pacemaker, November 17, 2008
Medtronic completes CryoCath buyout, November 13, 2008
Copyright © 2009 AuntMinnie.com
